Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided pembrolizumab + azacitidine in NPM1-mutated AML with imminent relapse
2017-004110-25Phase 2Active
- Sponsor
- Technische Universität Dresden
- Start
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and azacitidine in acute myeloid leukemia (AML), sponsored by Technische Universität Dresden. Primary endpoint: Event-free status at 24 weeks. Started Aug 2018; status: active.
02
Drugs
pembrolizumabazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2017-004110-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004110-25.